Search
VP025
go.drugbank.com/drugs/DB05133ExperimentalVP025, a novel drug formulation based on phospholipid microparticles incorporating phosphatidylglycerol, can inhibit neuroinflammation. … chronic inflammation within the central nervous system that is associated with a number of neurological diseases, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (Lou
Ethylmorphine
go.drugbank.com/drugs/DB01466IllicitInvestigationalIt is metabolized in the liver by ethylmorphine-N-demethylase and used as an indicator of liver function. It is not marketed in the US but is approved for use in various countries around the world. … In the US it is a schedule II drug (single-entity) and schedule III drug (in combination products).
Camizestrant
go.drugbank.com/drugs/DB19218ApprovedInvestigational[L64094,L64107] Patients are selected for treatment on the basis of an *ESR1* mutation detected by circulating tumor DNA testing during first-line endocrine therapy, before radiographic disease progression … [L64094,L64107] It binds the ligand binding domain of ERα, antagonizing ERα encoded by both wild-type and mutated *ESR1* and inducing proteasome-dependent degradation of the receptor without agonizing
Buclizine
go.drugbank.com/drugs/DB00354ApprovedIt was manufactured by Stuart Pharms and initially approved by the FDA in 1957. … Buclizine is an antihistamine medication with both antiemetic and anticholinergic effects [L6220], belonging to the _piperazine derivative_ family of drugs.
Lurasidone
go.drugbank.com/drugs/DB08815ApprovedInvestigationalLurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S.
Plerixafor
go.drugbank.com/drugs/DB06809ApprovedInvestigational[A7115] Plerixafor has orphan drug status in the United States and European Union and was approved by the US Food and Drug Administration on December 15, 2008.[A7117,L45678] … These stem cells are then collected and used in autologous stem cell transplantation to replace blood-forming cells destroyed by chemotherapy.
Cenegermin
go.drugbank.com/drugs/DB13926ApprovedInvestigational[L4563] While the prevalence of neurotrophic keratitis is low, the impact of this serious condition and its associated sequelae on an individual patient can be debilitating. … Cenegermin received approval from the US FDA a year later in August of 2018. [L4563] Neurotrophic keratitis is a degenerative disease resulting from a loss of corneal sensation.
Milrinone
go.drugbank.com/drugs/DB00235ApprovedInvestigational[A228333] It was approved by the FDA on December 31, 1987, and was marketed under the trademark PRIMACOR® by Sanofi-Aventis US before being discontinued.[L31483] … Often the result of long-term myocardial ischemia, cardiomyopathy, or other cardiac insults, heart failure results from an inability of the heart to perfuse peripheral tissues with sufficient oxygen and
Dimetindene
go.drugbank.com/drugs/DB08801ApprovedInvestigationalDimetindene (Fenistil) is an antihistamine/anticholinergic used orally and locally as an antipruritic.
Lemborexant
go.drugbank.com/drugs/DB11951ApprovedInvestigational[L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to … Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.